Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024
Nicolas de Prost,Etienne Audureau,Antoine Guillon,Lynda Handala,Sébastien Préau,Aurélie Guigon,Fabrice Uhel,Quentin Le Hingrat,Flora Delamaire,Claire Grolhier,Fabienne Tamion,Alice Moisan,Cédric Darreau,Jean Thomin,Damien Contou,Amandine Henry,Thomas Daix,Sébastien Hantz,Clément Saccheri,Valérie Giordanengo,Tài Pham,Amal Chaghouri,Pierre Bay,Jean-Michel Pawlotsky,Slim Fourati,SEVARVIR investigators,Keyvan Razazi,Armand Mekontso Dessap,Raphaël Bellaïche,Lucile Picard,Alexandre Soulier,Mélissa N'Debi,Sarah Seng,Christophe Rodriguez,Frédéric Pene,Anne-Sophie L'Honneur,Adrien Joseph,Elie Azoulay,Maud Salmona,Marie-Laure Chaix,Charles-Edouard Luyt,David Levy,Julien Mayaux,Stéphane Marot,Juliette Bernier,Maxime Gasperment,Tomas Urbina,Hafid Ait-Oufella,Eric Maury,Laurence Morand-Joubert,Djeneba Bocar Fofana,Jean-François Timsit,Diane Descamps,Guillaume Voiriot,Nina de Montmollin,Mathieu Turpin,Stéphane Gaudry,Ségolène Brichler,Tài Olivier Pham,Elyanne Gault,Sébastien Jochmans,Aurélia Pitsch,Guillaume Chevrel,Céline Clergue,Kubab Sabah,Laurence Courdavault Vagh Weinmann,Claudio Garcia-Sanchez,Ferhat Meziani,Louis-Marie Jandeaux,Samira Fafi-Kremer,Elodie Laugel,Sébastien Preau,Aurélie Guignon,Antoine Kimmoun,Evelyne Schvoerer,Cédric Hartard,Charles Damoisel,Nicolas Brechot,Helene Péré,François Beloncle,Francoise Lunel Fabiani,Rémi Coudroy,Arnaud W Thille,François Arrive,Sylvain le Pape,Laura Marchasson,Luc Deroche,Nicolas Leveque,Vincent Thibaut,Béatrice la Combe,Séverine Haouisee,Alexandre Boyer,Sonia Burrel,Gaetan Beduneau,Christophe Girault,Maximillien Grall,Dorothée Carpentier,Jean-Christophe Plantier,Emmanuel Canet,Audrey Rodallec,Berthe Marie Imbert,Sami Hraeich,Pierre-Edouard Fournier,Philippe Colson,Anaïs Dartevel,Sylvie Larrat,Guillaume Thiery,Sylvie Pillet,Kada Klouche,Edouard Tuaillon,Cécile Aubron,Adissa Tran,Sophie Vallet,Pierre-Emmanuel Charles,Alexis le Rougemont,Bertrand Souweine,Cecile Henquell,Audrey Mirand,Bruno Mourvillier,Laurent Andreoletti,Clément Lier,Damien du Cheyron,Nefert Candace Dossou,Astrid Vabret,Gaël Piton,Quentin Lepiller,Sylvie Roger
DOI: https://doi.org/10.1186/s13613-024-01319-w
2024-06-28
Abstract:Background: A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. However, no clinical data are available regarding critically-ill JN.1 COVID-19 infected patients. Methods: The current study is a substudy of the SEVARVIR prospective multicenter observational cohort study. Patients admitted to any of the 40 participating ICUs between November 17, 2022, and January 22, 2024, were eligible for inclusion in the SEVARVIR cohort study (NCT05162508) if they met the following inclusion criteria: age ≥ 18 years, SARS-CoV-2 infection confirmed by a positive reverse transcriptase-polymerase chain reaction (RT-PCR) in nasopharyngeal swab samples, ICU admission for acute respiratory failure. The primary clinical endpoint of the study was day-28 mortality. Evaluation of the association between day-28 mortality and sublineage group was conducted by performing an exploratory multivariable logistic regression model, after systematically adjusting for predefined prognostic factors previously shown to be important confounders (i.e. obesity, immunosuppression, age and SOFA score) computing odds ratios (OR) along with their corresponding 95% confidence intervals (95% CI). Results: During the study period (November 2022-January 2024) 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p = 0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p = 0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Only one JN-1 infected patient (1.8%) required extracorporeal membrane oxygenation support during ICU stay (vs 0/126 in the XBB group; p = 0.30). Day-28 mortality of JN.1-infected patients was 14.6%, not significantly different from that of XBB-infected patients (22.0%; p = 0.28). In univariable logistic regression analysis and in multivariable analysis adjusting for confounders defined a priori, we found no statistically significant association between JN.1 infection and day-28 mortality (adjusted OR 1.06 95% CI (0.17;1.42); p = 0.19). There was no significant between group difference regarding duration of stay in the ICU (6.0 [3.5;11.0] vs 7.0 [4.0;14.0] days; p = 0.21). Conclusions: Critically-ill patients with Omicron JN.1 infection showed a different clinical phenotype than patients infected with the earlier XBB sublineage, including more frequent obesity and less immunosuppression. Compared with XBB, JN.1 infection was not associated with higher day-28 mortality.